Alert: New Earnings Report (5/1/24)-TG Therapeutics Inc (NASDAQ: TGTX).

out_logo_500#25170.jpg

TG Therapeutics Inc (NASDAQ: TGTX) has reported a loss for its first fiscal quarter (ending March 31) of $-0.07 versus a loss $-0.28 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $0.29 versus $-1.23 for the same period a year ago.

Recent Price Action

out_mm#25170.jpg
TG Therapeutics Inc (NASDAQ: TGTX) stock closed at $15.88 on 5/1/24 after a major increase of 16.3%. Moreover, trading volume in this advance was exceptionally high at 502% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 11.4% during the last week.

Current PriceTarget Research Rating

TGTX is expected to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.

TG Therapeutics has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. TG Therapeutics has a neutral Appreciation Score of 55 but a very high Power Rating of 86, leading to the Positive Value Trend Rating.

Rating Review

In light of this new information and very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.


*